Dark Pharma · DP-040
SHE RAN THE META-ANALYSIS IN 2006. THE REVIEW HAPPENED AT SENIOR LEVEL. SHE KEPT BOTH DOCUMENTS.
In 2006, a senior statistician revealed that Cardiozan increased heart attack risk by 43%. Despite these findings being presented to executive leadership, the drug remained on the market for four additional years, generating £2.1 billion in revenue.
Case Assets
The Case Debrief is free to view. Full Case Study, Teaching Notes, Slide Deck, Discussion Guide, and Assessment are available with a Premium subscription.
Brief the Board
PREMIUM
🔒 Unlock
Learn the Case
FREE — included
Study the Case
PREMIUM
🔒 Unlock
Teach the Case
PREMIUM
🔒 Unlock
Present the Case
PREMIUM
🔒 Unlock
Run a Team Discussion
PREMIUM
🔒 Unlock
Test Your Judgement
PREMIUM
🔒 Unlock
Watch the Full Episode
The complete cinematic audio documentary — Dark Pharma
Unlock the Full Case Library
Get every Case Study, Slide Deck, Teaching Notes, Discussion Guide, and Assessment — across a growing library of business cases.
View Pricing →Related Cases
Cases that share a governance or behavioural model with this one.
Empire Builders
EB-047
I VOTED YES ON NOVEMBER 18TH. THE REAL ESTATE REIT WAS ALREADY INCORPO...
Shared: Independent Oversight, Risk Management Framework
Dark Law
DL-027
HE WORE THE WIRE TO FORTY-FIVE MEETINGS. THE FBI CALLED HIM THEIR BEST...
Shared: Risk Management Framework, Whistleblower Policy
Machine Room
MX-037
SHE SET THE THRESHOLD AT EIGHTY-SEVEN PERCENT. FLEETRIDE TERMINATED SI...
Shared: Risk Management Framework, Continuous Improvement Cycle
Dark Pharma
DP-023
SHE PAID THEM TWELVE DOLLARS. THEY CAME BACK TWICE A WEEK. THE MEDICIN...
Shared: Ethical Decision-Making Model, Risk Management Framework